Prokidney Corp (PROK) Stock Price, Quote & News

Company Profile

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in...

Industry: Biotechnology

Sector: Healthcare

Phone: 336 999 7019

Website: prokidney.com

Address:

2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, United States

GJ_Rockabilt Sep. 3 at 7:18 AM

$PROK

0 · Reply

SmartWentCrazy Aug. 28 at 2:24 PM

$PROK textbook short and distort shake off. Can’t believe some of y’all fell for it. Research pays.

0 · Reply

SanKish Aug. 28 at 2:41 AM

$PROK this reversed pretty nicely from last 2 week’s doom and gloom. I thought the next trigger is in 27 so what’s driving the price up?

2 · Reply

BiotechButterflies Aug. 27 at 10:03 PM

$PROK ... patience.... data comi g in 27....what a cool solution.... fi gers crossed.... could be massive....

0 · Reply

HawkEye828 Aug. 24 at 1:06 PM

$PROK Nice Accumulation going on with this stock. Buy and Hold. Here is More educational info on Prok. This is a big deal! Government savings would be huge. National Kidney Foundation indicates Medicare actually spends $130 Bilion--moe then 24% of total spending on kidney disease. https://www.kidney.org/take-action/advocate/legislative-priorities/federal-investment J.P. Morgan conference--Phase 2 complete. 78% response rate with kidney stabilization. This is an Autologous treatment, using the patients own kidney cells. Alligned with FDA for Accelerated approval. Phase 3 on board. https://investors.prokidney.com/static-files/9159cbbe-5e36-468c-9c58-f3b3cc4fc428 $MRNA, $RHHBY, $LLY, $ABBV

0 · Reply

Jaymuss Aug. 21 at 9:27 PM

$PROK Pretty established trend line to break, otherwise more of the same manipulation...

0 · Reply

SmartWentCrazy Aug. 21 at 2:04 PM

$PROK 1.52 is a huge level. Could really use a break above

1 · Reply

discocelsior1 Aug. 21 at 10:23 AM

$PROK shit is dead, when will we get a update

0 · Reply

HawkEye828 Aug. 19 at 1:39 PM

Go Merck...PROK will easily blow past 95% once Rilparencel is appoved for Chronic Kidney disease. $PROK Analysts Sentiment Buy Price Target 6.250 Upside +369.92% prokidney.com/clinical-stud.... Phase 2 with 70% response rate for kidney disease. Phase 3 on deck. Riprencel cell therapy designed to delay or completely prevent the need for dialysis which is one of the highest Medicare expenses ...at $30 Billion a year/ 90k to 100k per patient. $RHHBY, $NVO, $LLY, $ABBV

1 · Reply

ajmrtxl Aug. 18 at 4:25 PM

$PROK 's latest squeeze play

0 · Reply

20 stocks likely to lose money even if the bull market continues

ALOY AMLX CD CRML EVCM FBYD FJET

2026-08-10T20:45:17.000Z - 23 days ago

ProKidney reports Q2 EPS (15c), consensus (14c)

Aug 10, 2026, 7:00 AM EDT - 23 days ago

ProKidney Quarterly report: Q2 2026

Aug 10, 2026, 7:00 AM EDT - 23 days ago

ProKidney Earnings release: Q2 2026

Jun 4, 2026, 7:35 AM EDT - 3 months ago

ProKidney Transcript: Jefferies Global Healthcare Conference 2026

2026-06-02T13:29:40.000Z - 3 months ago

ProKidney appoints Kenneth Locke as chief technical officer

Jun 2, 2026, 8:00 AM EDT - 3 months ago

ProKidney Appoints Kenneth Locke as Chief Technical Officer

May 28, 2026, 10:00 AM EDT - 3 months ago

ProKidney Transcript: AGM 2026

2026-05-15T16:03:34.000Z - 3 months ago

ProKidney reports Q1 EPS (14c), consensus (14c)

2026-05-15T16:02:54.000Z - 3 months ago

ProKidney sees cash runway into mid-2027

May 15, 2026, 11:45 AM EDT - 3 months ago

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

May 15, 2026, 7:00 AM EDT - 3 months ago

ProKidney Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

ProKidney Earnings release: Q1 2026

Apr 17, 2026, 8:00 AM EDT - 4 months ago

ProKidney Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

ProKidney Proxy statement: Proxy filing

2026-03-25T20:05:32.000Z - 5 months ago

ProKidney appoints Greg Madison as chief commercial officer

Mar 25, 2026, 4:01 PM EDT - 5 months ago

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

2026-03-18T20:05:15.000Z - 5 months ago

ProKidney reports Q4 EPS (52c), consensus (15c)

Mar 18, 2026, 7:00 AM EDT - 5 months ago

ProKidney Earnings release: Q4 2025

Mar 18, 2026, 7:00 AM EDT - 5 months ago

ProKidney Annual report: Q4 2025

Jan 14, 2026, 11:15 AM EST - 7 months ago

ProKidney Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 11:15 AM EST - 7 months ago

ProKidney Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 7 months ago

ProKidney Slides: Corporate presentation

Jan 6, 2026, 7:30 AM EST - 7 months ago

ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-16T11:10:10.000Z - 8 months ago

ProKidney initiated with a Buy at H.C. Wainwright

Nov 12, 2025, 10:00 AM EST - 9 months ago

ProKidney Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-10T21:55:28.000Z - 9 months ago

ProKidney reports Q3 EPS (12c), consensus (14c)

Nov 10, 2025, 4:15 PM EST - 9 months ago

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

Nov 10, 2025, 4:00 PM EST - 9 months ago

ProKidney Earnings release: Q3 2025

Nov 10, 2025, 4:00 PM EST - 9 months ago

ProKidney Quarterly report: Q3 2025

Nov 9, 2025, 6:00 PM EST - 9 months ago

ProKidney Slides: Corporate Presentation

2025-11-06T16:06:09.000Z - 10 months ago

ProKidney presents results from Phase 2 REGEN-007 trial of rilparencel

Nov 6, 2025, 11:00 AM EST - 10 months ago

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025

Oct 29, 2025, 7:30 AM EDT - 10 months ago

ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference

Oct 20, 2025, 7:30 AM EDT - 10 months ago

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025

Sep 8, 2025, 7:00 AM EDT - 11 months ago

ProKidney Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 10:30 AM EDT - 12 months ago

ProKidney Transcript: Citi's Biopharma Back to School Conference

Aug 27, 2025, 7:30 AM EDT - 1 year ago

ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference

2025-08-12T20:22:53.000Z - 1 year ago

ProKidney reports Q2 EPS (13c), consensus (14c)

Aug 12, 2025, 4:01 PM EDT - 1 year ago

ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

Aug 12, 2025, 7:00 AM EDT - 1 year ago

ProKidney Earnings release: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 1 year ago

ProKidney Quarterly report: Q2 2025

2025-07-15T11:35:55.000Z - 1 year ago

ProKidney announces alignment with FDA on rilparencel accelerated approval path

Jul 15, 2025, 7:30 AM EDT - 1 year ago

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel

2025-07-15T11:02:04.000Z - 1 year ago

ProKidney price target raised to $8 from $4 at UBS

Jul 15, 2025, 7:00 AM EDT - 1 year ago

ProKidney Slides: Corporate Presentation

Jul 14, 2025, 1:30 PM EDT - 1 year ago

ProKidney Transcript: H.C. Wainwright 4th Annual Kidney Virtual Conference

2025-07-14T12:12:42.000Z - 1 year ago

ProKidney price target raised to $7 from $6 at Guggenheim

Jul 9, 2025, 11:22 AM EDT - 1 year ago

Trump's latest tariff threats and the impact on markets, ProKidney stock jumps over 500%

Jul 9, 2025, 8:45 AM EDT - 1 year ago

ProKidney: What's Happening With PROK Stock?

Jul 9, 2025, 7:30 AM EDT - 1 year ago

ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

2025-07-09T00:31:00.000Z - 1 year ago

Why Is ProKidney Stock (PROK) Up 60% Today?

Jul 8, 2025, 5:09 PM EDT - 1 year ago

ProKidney's stock rockets on ‘intriguing' news, but analyst doesn't recommend buying

2025-07-08T21:00:31.000Z - 1 year ago

ProKidney price target raised to $9 from $6 at Citi

Jul 8, 2025, 7:00 AM EDT - 1 year ago

ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes

Jul 1, 2025, 12:43 PM EDT - 1 year ago

ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware

May 12, 2025, 4:15 PM EDT - 1 year ago

ProKidney Reports First Quarter 2025 Financial Results and Business Highlights

May 12, 2025, 12:30 PM EDT - 1 year ago

ProKidney Earnings release: Q1 2025

May 12, 2025, 12:30 PM EDT - 1 year ago

ProKidney Quarterly report: Q1 2025

Mar 17, 2025, 9:30 AM EDT - 1 year ago

ProKidney Annual report: Q4 2024

Mar 17, 2025, 9:30 AM EDT - 1 year ago

ProKidney Earnings release: Q4 2024

Mar 17, 2025, 7:30 AM EDT - 1 year ago

ProKidney Reports Full Year 2024 Financial Results and Business Highlights

Jan 31, 2025, 11:08 AM EST - 1 year ago

Kuehn Law Encourages Investors of ProKidney Corp. to Contact Law Firm

Jan 15, 2025, 10:30 AM EST - 1 year ago

ProKidney Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 10:30 AM EST - 1 year ago

ProKidney Slides: FY 2025

Dec 3, 2024, 8:45 AM EST - 1 year ago

ProKidney Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 26, 2024, 7:30 AM EST - 1 year ago

ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference

Nov 20, 2024, 5:00 AM EST - 1 year ago

ProKidney Transcript: Jefferies London Healthcare Conference 2024

Nov 13, 2024, 10:30 AM EST - 1 year ago

ProKidney Transcript: Guggenheim’s Inaugural Healthcare Innovation Conference

Nov 12, 2024, 7:30 AM EST - 1 year ago

ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting

Nov 12, 2024, 7:00 AM EST - 1 year ago

ProKidney Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

ProKidney Earnings release: Q3 2024

Nov 5, 2024, 7:30 AM EST - 1 year ago

ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference

Oct 15, 2024, 9:00 AM EDT - 1 year ago

ProKidney Transcript: UBS Virtual Organ Restoration and Cell Therapy Day

Oct 14, 2024, 7:30 AM EDT - 1 year ago

ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2024

Oct 9, 2024, 7:30 AM EDT - 1 year ago

ProKidney to Participate in the UBS Virtual Organ Restoration Day

Sep 5, 2024, 7:00 AM EDT - 1 year ago

ProKidney Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 3, 2024, 7:30 AM EDT - 1 year ago

ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S.

Aug 27, 2024, 7:30 AM EDT - 2 years ago

ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 9, 2024, 7:00 AM EDT - 2 years ago

ProKidney Reports Business Updates and Second Quarter 2024 Financial Results

Aug 9, 2024, 7:00 AM EDT - 2 years ago

ProKidney Quarterly report: Q2 2024

Aug 9, 2024, 7:00 AM EDT - 2 years ago

ProKidney Earnings release: Q2 2024

Jun 11, 2024, 9:35 PM EDT - 2 years ago

ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering

Jun 10, 2024, 4:15 PM EDT - 2 years ago

ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering

Jun 10, 2024, 8:00 AM EDT - 2 years ago

ProKidney Transcript: Study Update

Jun 10, 2024, 8:00 AM EDT - 2 years ago

ProKidney Press release: Study Update

Jun 10, 2024, 8:00 AM EDT - 2 years ago

ProKidney Slides: Study Update

Jun 10, 2024, 6:30 AM EDT - 2 years ago

ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates

May 29, 2024, 7:00 AM EDT - 2 years ago

ProKidney to Participate in the Jefferies Global Healthcare Conference

May 28, 2024, 8:00 AM EDT - 2 years ago

ProKidney Transcript: Status Update

May 28, 2024, 8:00 AM EDT - 2 years ago

ProKidney Slides: Status Update

May 21, 2024, 7:00 AM EDT - 2 years ago

ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024

May 10, 2024, 7:00 AM EDT - 2 years ago

ProKidney Reports Business Updates and First Quarter 2024 Financial Results

May 10, 2024, 7:00 AM EDT - 2 years ago

ProKidney Quarterly report: Q1 2024

May 10, 2024, 7:00 AM EDT - 2 years ago

ProKidney Earnings release: Q1 2024

Apr 26, 2024, 8:00 AM EDT - 2 years ago

ProKidney Proxy statement: Proxy Filing

Mar 25, 2024, 6:05 AM EDT - 2 years ago

ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations

Mar 21, 2024, 7:49 PM EDT - 2 years ago

ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights

Mar 21, 2024, 7:00 AM EDT - 2 years ago

ProKidney Earnings release: Q4 2023

Mar 21, 2024, 7:00 AM EDT - 2 years ago

ProKidney Annual report: Q4 2023

Feb 29, 2024, 4:05 PM EST - 2 years ago

ProKidney to Participate in Jefferies Biotech on the Bay Summit

Nov 30, 2023, 7:55 AM EST - 2 years ago

ProKidney Transcript: The 6th Annual Evercore ISI HealthCONx Conference

Nov 30, 2023, 6:05 AM EST - 2 years ago

ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer

Nov 22, 2023, 7:00 AM EST - 2 years ago

ProKidney Registration statement: Registration Filing

Nov 21, 2023, 6:05 AM EST - 2 years ago

ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference

Nov 14, 2023, 8:00 AM EST - 2 years ago

ProKidney Earnings Call Transcript: Q3 2023

Nov 14, 2023, 8:00 AM EST - 2 years ago

ProKidney Quarterly report: Q3 2023

Nov 14, 2023, 8:00 AM EST - 2 years ago

ProKidney Earnings release: Q3 2023

Nov 14, 2023, 8:00 AM EST - 2 years ago

ProKidney Slides: Q3 2023

Nov 14, 2023, 6:05 AM EST - 2 years ago

ProKidney Reports Third Quarter Financial Results

Nov 13, 2023, 5:02 PM EST - 2 years ago

ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates

Oct 30, 2023, 4:12 PM EDT - 2 years ago

ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2023

Sep 11, 2023, 12:15 PM EDT - 2 years ago

ProKidney Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Sep 5, 2023, 6:05 AM EDT - 2 years ago

ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference

Aug 10, 2023, 4:10 PM EDT - 3 years ago

ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights

Aug 10, 2023, 8:00 AM EDT - 3 years ago

ProKidney Quarterly report: Q2 2023

Aug 10, 2023, 8:00 AM EDT - 3 years ago

ProKidney Earnings release: Q2 2023

Jul 18, 2023, 6:05 AM EDT - 3 years ago

ProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NC

Jul 15, 2023, 2:02 AM EDT - 3 years ago

ProKidney Appoints Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization

Jun 13, 2023, 12:05 PM EDT - 3 years ago

ProKidney Announces Purchase of Manufacturing Facility in Greensboro, NC

Jun 1, 2023, 4:05 PM EDT - 3 years ago

ProKidney to Participate in Fireside Chat at the Jefferies Healthcare Conference

May 26, 2023, 8:00 AM EDT - 3 years ago

ProKidney Proxy statement: Proxy Filing

May 11, 2023, 4:01 PM EDT - 3 years ago

ProKidney Reports First Quarter Financial Results and Recent Corporate Highlights

GJ_Rockabilt Sep. 3 at 7:18 AM

$PROK

0 · Reply

SmartWentCrazy Aug. 28 at 2:24 PM

$PROK textbook short and distort shake off. Can’t believe some of y’all fell for it. Research pays.

0 · Reply

SanKish Aug. 28 at 2:41 AM

$PROK this reversed pretty nicely from last 2 week’s doom and gloom. I thought the next trigger is in 27 so what’s driving the price up?

2 · Reply

BiotechButterflies Aug. 27 at 10:03 PM

$PROK ... patience.... data comi g in 27....what a cool solution.... fi gers crossed.... could be massive....

0 · Reply

HawkEye828 Aug. 24 at 1:06 PM

0 · Reply

Jaymuss Aug. 21 at 9:27 PM

$PROK Pretty established trend line to break, otherwise more of the same manipulation...

0 · Reply

SmartWentCrazy Aug. 21 at 2:04 PM

$PROK 1.52 is a huge level. Could really use a break above

1 · Reply

discocelsior1 Aug. 21 at 10:23 AM

$PROK shit is dead, when will we get a update

0 · Reply

HawkEye828 Aug. 19 at 1:39 PM

1 · Reply

ajmrtxl Aug. 18 at 4:25 PM

$PROK 's latest squeeze play

0 · Reply

Whiskeyunderthebed Aug. 17 at 6:25 PM

$PROK https://youtu.be/ImpPYKtK2AE

0 · Reply

HawkEye828 Aug. 17 at 12:33 PM

$PROK Analysts Sentiment Buy Price Target 6.250 Upside +369.92% https://prokidney.com/clinical-studies/#:~:text=Rilparencel%20is%20being%20developed%20to,the%20patient's%20own%20kidney%20cells. Phase 2 with 70% response rate for kidney disease. Phase 3 on deck. Riprencel cell therapy designed to delay or completely prevent the need for dialysis which is one of the highest Medicare expenses ...at $30 Billion a year/ 90k to 100k per patient. $RHHBY, $NVO, $LLY, $ABBV

1 · Reply

BiotechButterflies Aug. 15 at 7:13 PM

$PROK one of my hopefuls that ph3 works well and mnfg good... these folks have interesting backers... and damm.. my dad needed dialysis so if this could help folks like him... a total game changer... betting here on ok pos and a hope and prayer this works and gets to patients... will know early 27?

2 · Reply

HawkEye828 Aug. 14 at 6:59 PM

$PROK No reason for this to be down...great opportunity to load. This will be a multibagger. No brainer. On target for kidney drug that will save the government in Billions in dialysis. 70 % positive response rate. ProKidney (NASDAQ: PROK) is a clinical-stage biotechnology company founded in 2015 and headquartered in Winston-Salem, North Carolina. It is focused on developing a first-of-its-kind autologous cell therapy named rilparencel (REACT®) designed to preserve kidney function and delay or prevent the need for dialysis in patients with advanced chronic kidney disease (CKD) $LLY ,$AMGN, $VRTX, $GILD

0 · Reply

SmartWentCrazy Aug. 14 at 5:16 PM

$PROK yeah, they’ve just been building out their manufacturing facilities - I’m sure they’ve put zero thought into their strategic investment capital plans. 🤣

0 · Reply

ajmrtxl Aug. 14 at 10:57 AM

$PROK 's latest data on SqueezeFinder

0 · Reply

kingrichard1234 Aug. 13 at 6:48 PM

$PROK So basically management have said they wont have enough funds to finish the trails and will need to sell more shares next year? is that the way you take it ?

5 · Reply

Biohacker Aug. 12 at 2:40 PM

$PROK 💩

0 · Reply

SmartWentCrazy Aug. 11 at 4:56 PM

$PROK essentially no news today. We already knew the funding is tight around read out, and it didn’t take a rocket scientist to notice they removed their intake for the PHASE 3 trials from the website and trial site.

1 · Reply

Biohacker Aug. 11 at 12:32 PM

$PROK Well at least they are on track .Any delay in this report and it would have been -30% day .Now it’s just dead money until Q2 2027 Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027 -- On track for completion of full enrollment for PROACT 1 in the second half of 2026 -- Appointed Kenneth Locke as Chief Technical Officer, adding more than 25 years of R&D, CMC and supply chain leadership experience -- Ended Q2 2026 with $181.6 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027

2 · Reply

Merlintrader Aug. 1 at 6:10 PM

ProKidney ($PROK): Rilparencel, PROACT 1 and the Unconfirmed Mid-2026 Enrollment Checkpoint https://www.merlintrader.com/prokidney-stock-hub/

0 · Reply

ajmrtxl Jul. 29 at 4:38 PM

$PROK 's latest data on SqueezeFinder

0 · Reply

Market Cap	559.30M
Revenue (ttm)	890,000.00
Net Income (ttm)	-68.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,751.69%
Debt to Equity Ratio	0.00

Volume	641,200
Avg Vol	1,331,220
Day's Range	N/A - N/A
Shares Out	302.32M
Stochastic %K	92%
Beta	1.70
Analysts	Sell
Price Target	$5.50